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Summary 21 
The anaphylactoid reaction described follows cessation of ranitidine in a 19 year old female with the 22 
disease cluster: mast cell activation syndrome, hypermobile Ehlers-Danlos syndrome and postural 23 
tachycardia syndrome. 24 
Anaphylaxis can give wide-ranging symptoms from rhinorrhoea and urticaria to tachycardia and 25 
system-wide, life-threatening, anaphylactic shock. Individuals with a disorder of mast cell activation 26 
can experience many such symptoms. H2 receptor antagonists, such as ranitidine, are commonly 27 
prescribed in this population.  28 
A mechanism for the reaction is proposed in the context of ranitidine, as an inverse agonist, causing 29 
upregulation of H2 histamine receptors and raised histamine levels due to enzyme induction. This 30 
effect, following extended and/or high antihistamine dosing, may have implications for other 31 
individuals with a disorder of mast cell activation, such as mastocytosis or mast cell activation 32 
syndrome. There are potential policy and patient guidance implications for primary and secondary 33 
care with respect to cessation of H2 antagonists. 34 
 35 
Key words: ranitidine, mast cell activation, histamine, upregulation, anaphylaxis 36 
What is already known 37 
 Ranitidine, H2-receptor antagonist (inverse agonist): 38 
- can manage symptoms associated with gastric hyperacidity and mast cell activation 39 
- has caused: anaphylaxis (rare) upon initiation; intragastric hyperacidity on cessation 40 
 Sustained H2 antagonism can: upregulate receptors; alter levels of histamine synthesizing and 41 
metabolizing enzymes  42 
 H1/H2 cross-desensitisation has been reported 43 
 44 
What this paper adds 45 
 Observed anaphylactoid symptoms on stopping ranitidine (in an individual with mast cell 46 
activation syndrome) 47 
 A proposed mechanism relating to: 48 
- upregulation of histamine receptors 49 
- raised histamine levels due to altered transmitter turnover  50 
- receptor cross-talk. 51 
 There may be policy implications for cessation of H2 antagonists  52 
 53 
Introduction 54 
Anaphylaxis, a type-1 hypersensitivity response, can be a life-threatening event caused by flooding 55 
of mast and basophil cell-derived mediators in response to a stimulus. Drug-induced anaphylaxis has 56 
increased in frequency with the advent and administration of a widening array of therapeutic 57 
agents. Ranitidine, an H2 receptor antagonist, is one such medication which has been reported, 58 
albeit rarely, to cause anaphylaxis upon initiation [1]. Although hyperacidity following cessation of 59 
ranitidine has been well-documented, to the best of our knowledge, wider histaminergic symptoms 60 
have not. 61 
Developed following the pioneering work of Black et al. (1972), ranitidine has been widely 62 
prescribed since its introduction to the market in 1981 and was a first choice to reduce gastric acid 63 
output in gastro-oesophageal reflux disease, functional dyspepsia, and benign gastric or duodenal 64 
ulceration [2]. Although its use has been to a large extent superseded by proton pump inhibitors 65 
(PPI), such as lansoprazole and omeprazole, it is still widely prescribed and is also available to 66 
purchase in lower strength formulations from UK pharmacies and other retail outlets. Individuals 67 
with hypermobile Ehlers-Danlos syndrome and/or a disorder of mast cell activation can be 68 
prescribed ranitidine to manage gastric symptoms. 69 
The Ehlers-Danlos syndromes (EDS) are rare heritable disorders of connective tissues. These 70 
syndromes have until recently been classified under the Villefranche Nosology, which described six 71 
subtypes of the disorder. In March 2017 the International EDS Consortium proposed a revised 72 
classification of thirteen EDS subtypes [3]. Hypermobile EDS (hEDS) is the most common of these 73 
subtypes with a prevalence of 1-5 per 10,000 individuals. hEDS is diagnosed by satisfying clinical 74 
criteria relating to generalised joint hypermobility, family history, and the presence or absence of 75 
signs and symptoms of other connective tissue disorders [3]. Functional gastro-intestinal problems 76 
are common and individuals can suffer gastric reflux, nausea, abdominal discomfort and altered gut 77 
transit times, leading to both constipation and diarrhoea [4,5]. 78 
Disorders associated with mast cell activation include mastocytosis and the poorly understood mast 79 
cell activation syndrome (MCAS, or idiopathic MCAS). Current proposed MCAS diagnostic criteria 80 
are: episodic multisystem symptoms consistent with mast cell activation (which can be due to both 81 
IgE- and non-IgE-mediated triggers); appropriate response to medication that targets mast cell 82 
activation; documented increases in validated systemic markers of mast cell activation during a 83 
symptomatic period compared with the patient’s baseline values [6]. However, mast cell activation 84 
that is associated with another chronic inflammatory disease does not always meet the diagnostic 85 
criteria and can be difficult to diagnose [7,8]. In these patients there is commonly a history of 86 
multisystem morbidity of an inflammatory or allergic nature and features of inappropriate mast cell 87 
activation, but without evidence of mast cell proliferation [9].  It has further been proposed that lack 88 
of raised tryptase, where there is evidence of elevated histamine, suggests involvement of basophils, 89 
and that gastric signs and symptoms appear to be more associated with raised histamine than 90 
tryptase [10,11]. An association between hEDS, MCAS and postural tachycardia syndrome (PoTS) has 91 
been identified [12]. 92 
The biogenic amine histamine is synthesized and stored in “professional” basophils and mast cells 93 
and released through exocytosis to play a central role in inflammatory or allergic reactions. Four 94 
histamine receptor subtypes have been identified, H1, H2, H3 and H4; all are G protein-coupled 95 
receptors (GPCRs) [13]. Constitutive or spontaneous activity, where a receptor response can be 96 
generated in the absence of bound agonist, has been shown for many GPCRs including histamine 97 
receptors [14,12]. According to the two-state model for GPCR function, receptors can switch 98 
between resting and activated states. Where constitutive activity occurs, a proportion of receptors 99 
exists in the active conformation in the absence of bound ligand. Agonists tend to shift the 100 
equilibrium towards the active receptor state, while inverse agonists shift it towards the resting 101 
state [15,16]. The H2 receptor ligand ranitidine is known to act as an inverse agonist at the H2 102 
histamine receptor [17]. 103 
Histamine is arguably the most pleiotropic chemical in the human body and its receptors have a 104 
wide distribution. H1 receptors are located in the central nervous system (CNS), smooth muscle, 105 
sensory nerves, heart, immune and skin cells, among others [13]. Stimulation of these receptors can 106 
give rise to symptoms due to: bronchiolar and gastrointestinal (GI) smooth muscle contraction 107 
(causing bronchospasm and difficulty breathing, and diarrhoea respectively); sensory stimulation of 108 
the epidermis and dermis (causing itch and pain); vasodilation (causing hypotension, flushing and 109 
headache) [16]. 110 
H2 receptors are also widely distributed and found in high concentrations in gastric mucosa, the 111 
uterus, CNS, heart and vasculature, respiratory tract, and cells involved in immune function [13,16]. 112 
The majority of histamine receptors in the skin are thought to be H1, with around fifteen percent 113 
being H2 [18]. Stimulation of H2 receptors promotes hydrochloric acid secretion from gastric parietal 114 
cells and can cause symptoms associated with gastric hyperacidity. H2 receptor stimulation in the 115 
cardiovascular system increases heart rate and contractility. 116 
H3 receptors are highly expressed in the CNS and have a wide distribution elsewhere in the body, 117 
including the GI tract, heart, skeletal muscle and sensory nervous system, including in the dermis 118 
[13]. Less is known about the most recently discovered H4 histamine receptor, although mRNA 119 
expression studies have indicated a wide distribution and particular abundance in cells of the 120 
immune system, including lymphocytes, monocytes, neutrophils, and eosinophils. H4 expression has 121 
also been demonstrated in the sensory nervous system, skin fibroblasts, GI tract and kidney [13]. 122 
Definitive demonstrations of protein and functional expression have, however, yet to be reported 123 
[13].  124 
The potentially life-threatening symptoms associated with anaphylaxis are multifaceted and include 125 
hypotension, bronchospasm, gastrointestinal symptoms, angio- and laryngeal oedema, cutaneous 126 
symptoms and hypothermia [19,20]. These symptoms are induced in susceptible individuals by 127 
diverse triggers, including certain foods, insect stings, stress and medication. Such triggers bring 128 
about release of the mediators of the pathophysiological effects seen in this serious allergic reaction 129 
in which histamine has a central role acting at its receptors located on the affected cells/organs. 130 
There is also evidence that histamine influences the activity of a number of inflammatory cell types 131 
and is implicated in allergic inflammation via all of the histamine receptors [21], with H3 and H4 132 
displaying notable high potency for histamine [13]. 133 
Case report  134 
Here we report anaphylactoid symptoms in a white British female aged 19 with co-morbidities of 135 
hEDS, MCAS and PoTS, which followed cessation of high-dose ranitidine and culminated in 136 
administration of adrenaline.  137 
Medication in the days preceding the anaphylactoid event were: cetirizine tablets 10mg, one at 138 
night; Slow Sodium tablets 600mg, 8 daily; paracetamol tablets 500mg, one or two when required, 139 
(not taken in the week prior to the event); ondansetron tablets 4mg, one when required (not taken 140 
in the week prior to the event); omeprazole tablets 10mg (not taken in the week prior to the event), 141 
two at night; and ranitidine 300mg tablets, one twice daily (dose increased from 300mg to 600mg 142 
daily, 5 weeks prior to the event).  143 
The patient had been advised to stop gastric acid-altering medication in readiness for a gastroscopy 144 
and had gradually reduced the dose of omeprazole over a one week period; dosing had stopped 10 145 
days prior to the anaphylactoid event. In the three days preceding the event ranitidine was reduced 146 
as follows: day 1 - morning dose was omitted and 300mg was taken in the evening; day 2 – morning 147 
dose was taken and further dosing stopped. The patient became symptomatic from the evening of 148 
day 3 onwards, with symptoms worsening from the morning of day 4. 149 
The patient had not experienced anaphylaxis before; the only IgE-mediated allergy she had shown 150 
previously was to latex. She had identified a number of food intolerances which caused gastric 151 
symptoms, but these symptoms had improved following the addition of H1 (cetirizine) and increased 152 
H2 (ranitidine) antihistamine medication. She was following a low-FODMAP (fermentable 153 
oligosaccharides, disaccharides, monosaccharides and polyols) diet [22] and low histamine diet and 154 
had not eaten anything different to normal in the days leading up to the event.  155 
Symptoms leading to administration of adrenaline  156 
On day 3 (described above), the patient experienced abdominal cramps and shivering in the evening 157 
and felt cold and dizzy. She woke through the night due to abdominal pain and felt shivery and cold 158 
and generally unwell. The abdominal pain continued the following morning and she described 159 
feeling shivery, having a running nose and a tight throat, and finding her breakfast hard to swallow. 160 
She described looking at her tongue in the mirror because it felt “weird”. She had not experienced 161 
these symptoms before. Despite symptoms she went to college but continued to feel cold and 162 
noticed a mild red blotchy rash on her arms and felt somewhat itchy all over. Her throat became 163 
more bothersome and her chest started to feel tight; at this point she sought medical attention.   164 
At the minor injuries unit she was seen immediately. On arrival at 11:07 she was given a 4mg stat 165 
dose of oral H1 antagonist, chlorphenamine. Recorded observations at 11:15 were: temperature 166 
36.6°C; pulse 96 beats/min; respiration rate 15 breaths/min; blood pressure 140/87 mmHg; oxygen 167 
saturation 99.8%. At 11:35 observations were: pulse 83 beats/min; respiration rate 20 breaths/min;, 168 
blood pressure 143/79 mmHg, oxygen saturation 100%. No flushing, urticaria, stridor or angioedema 169 
were observed. At 11:45 the tightness in her chest and throat increased, face flushed, oxygen 170 
saturation dropped to 92% and she was administered a stat dose of adrenaline (0.5ml, 1:1000) and 171 
oxygen was commenced. Symptoms rapidly abated and she was transferred to the general hospital 172 
for observation. She recovered quickly and fully. 173 
Discussion 174 
The case report describes the symptoms experienced by a 19 year old female following cessation of 175 
the H2 receptor antagonist ranitidine. The patient had been prescribed ranitidine to manage gastric 176 
symptoms associated with mast cell activation and had taken a 600mg daily dose for 5 weeks prior 177 
to the event described here, which coincided with withdrawal of the drug. The 600mg daily dose is 178 
at the licensed maximum and is consistent with recommended dosing for prophylaxis and healing of 179 
NSAID (non-steroidal anti-inflammatory drugs) -induced duodenal and gastric ulcers, and moderate 180 
to severe GORD (gastro-oesophageal reflux disease) [23]. A dose of 300mg daily is, however, more 181 
commonly seen in practice. 182 
The early symptoms of shivering, stomach cramps, giddiness (or dizziness, as described by the 183 
patient), rhinorrhoea and tongue and throat symptoms experienced by the patient are classic 184 
symptoms mediated by histamine, acting at its widely-distributed G protein-coupled receptors.  185 
H1 and H2 receptors are co-expressed by many cell types at varying densities, whilst H3 and H4 186 
receptors appear to have a more limited distribution [13]. Stimulation of H1, H2 and H3 receptors has 187 
been implicated in inducing hypothermia in rodents [20, 24, 25], and abdominal pain and diarrhoea 188 
in humans [25]. The patient’s subsequent symptoms of chest and throat tightness and flushing are 189 
also those of registered anaphylactic reactions attributed to H1 and H2 receptor stimulation [27]; a 190 
contribution from activated H3 and H4 receptors cannot be discounted.  191 
Fullarton and colleagues [28,29] reported the well-documented rebound nocturnal hyperacidity 192 
after abrupt withdrawal of a number of H2 receptor antagonists, including ranitidine. The authors 193 
proposed that the underlying mechanism responsible for this phenomenon could be upregulation of 194 
parietal cell H2 receptors. Since then, the concept of constitutive, or spontaneous, activity of many 195 
GPCRs has developed, including histamine receptors, in which a proportion of receptors exist in an 196 
active state in the absence of agonist [14]. Although almost all of these studies have been conducted 197 
in genetically-manipulated systems [reviewed in 13], it is important to note that spontaneous 198 
activity of H3 receptors has been recorded in a native system [30]. It seems likely that the related H2 199 
receptor also exhibits this behaviour in vivo.  200 
In 1996, using a transfected cell model, Smit et al. demonstrated that a number of H2 receptor 201 
antagonists, including ranitidine and cimetidine, acted as inverse agonists driving the receptor 202 
equilibrium towards the resting state. In doing so these ligands inhibit basal, agonist-independent, 203 
activity [17]. The authors described an increase in H2 receptor density following exposure to 204 
ranitidine and cimetidine that was both time- and dose-dependent. This upregulation led to 205 
increased basal ligand-independent activity which they suggested might underlie tolerance to these 206 
drugs and also contribute to the rebound hyperacidity experienced by patients. Jones et al. [31] 207 
observed an exaggerated response to a histamine analogue in patients who had been treated for 208 
three months with ranitidine at a dose of 150mg at night. They suggested that this observation 209 
reflected an increase in receptor number (or upregulation). Upregulation is believed to relate to 210 
suppression of H2 receptor degradation and the recycling of H2 receptors [32].  211 
Symptoms of rebound hyperacidity have been observed in patients between 24 and 48 hours after 212 
the final dose of H2 antagonist [29,33]. This is consistent with the appearance of the histaminergic 213 
symptoms in the case reported here, which began to develop 36 hours from the last dose of 214 
ranitidine and became severe at 48 hours. It is tempting to speculate that, in this case, chronic 215 
treatment with high dose ranitidine led to H2 receptor upregulation, giving rise to an increased 216 
population of spontaneously active receptors and resulting in H2 receptor-mediated histaminergic 217 
symptoms. 218 
It should be noted that the patient involved in this report had been diagnosed with MCAS, where 219 
symptoms are experienced as a result of excessive release of pro-inflammatory mediators, including 220 
histamine. In such a case, the consequences of ranitidine-induced receptor upregulation could 221 
conceivably be magnified, leading to extreme symptoms upon abrupt cessation of ranitidine dosing. 222 
An upregulation of H2 receptors might reasonably account for those symptoms that are obviously 223 
mediated by this class of receptor, such as abdominal discomfort. It is less clear how it could account 224 
for effects mediated by H1 (or H3 or H4) receptors. It has recently become apparent, however, that 225 
cross-talk exists between co-localized H1 and H2 receptors, with heterodimers forming and being co-226 
internalized when either receptor is stimulated [34,35]. Once internalized, these receptor dimers 227 
may contribute to signalling events and to the overall cellular response. If such events prove to be 228 
commonplace, this cross-talk between H1 and H2 receptors could explain the appearance of H1-229 
mediated symptoms, such as rhinorrhoea, that were experienced by this patient. 230 
Histamine is synthesized from histidine in a reaction catalysed by histidine decarboxylase (HDC). 231 
Monczor and Fernandez [34] described induction of this enzyme by the H2 receptor antagonist 232 
famotidine, resulting in increased levels of histamine, which the authors suggested could contribute 233 
to rebound hyperacidity [34]. Such an increase in histamine may be expected to evoke cellular 234 
effects mediated by all histamine receptors, and conceivably to an exaggerated response through 235 
the up-regulated population of H2 receptors following antagonist exposure, as seen in this patient.  236 
Animal studies have shown that the turnover of histamine varies in different tissues, with resultant 237 
differences in histamine half-life (t½) of minutes to several days [36]. This variation in histamine 238 
turnover has a number of possible explanations in addition to alterations in local tissue HDC. These 239 
include receptor-mediated changes in histamine metabolising enzymes (histamine N-methyl 240 
transferase, diamine oxidase), enzyme polymorphisms [37] and differences in histamine uptake 241 
activities (deranged histamine turnover). It has also been known for many years that in certain 242 
tissues, such as gastric mucosa, H2 receptor antagonists modulate histamine breakdown by 243 
histamine N-methyltransferase [38]. Differences in turnover of histamine in the various tissues 244 
affected could account for the timing of symptom onset experienced by the patient. 245 
Taken together, these findings offer a plausible explanation for the symptoms experienced by the 246 
patient, which were apparently precipitated by withdrawal of the H2 receptor antagonist ranitidine. 247 
It is proposed that upregulation of H2 receptors and/or increased levels of histamine underlie these 248 
effects. Through cross-talk between H1 and H2 receptors, activation of H1 receptors might also 249 
contribute to the full gamut of symptoms experienced by the patient. It is postulated that the 250 
severity of symptoms here was a consequence of the sustained duration of high-dose ranitidine, 251 
followed by its rapid removal, and the patient’s disorder of mast cell activation and hEDS.  252 
Patients with a disorder of mast cell activation (and also gastric symptoms associated with hEDS) can 253 
be prescribed both H1 and H2 antagonists at elevated doses that are above the manufacturer’s 254 
guidelines for the drug. This patient was prescribed ranitidine at the maximum dosage and cetirizine 255 
at the normal recommended dose. If this reaction had been predicted, increasing the dose of H1 256 
antagonist prior to ranitidine withdrawal might have reduced the adverse symptoms associated with 257 
cessation.  258 
Although hypotension is common in anaphylaxis, patients can also display hypertension which may 259 
be a stress response [39]. In the half hour leading up to the administration of adrenaline, two raised 260 
systolic readings were recorded in this patient. The effect of anxiety on blood pressure and in 261 
promoting further mediator release, thereby exacerbating symptoms in the hospital, cannot be 262 
ruled out. In addition, antagonising H2 receptors has been reported to modify the turnover of 5-263 
hydroxytryptamine (5-HT) [40], another mediator of anaphylaxis and modulator of mood. Mast cell 264 
5-HT, together with histamine released following intestinal anaphylaxis, can stimulate mesenteric 265 
afferents via 5-HT3 and histamine H1 (not H2 or H3) receptors. Information regarding intestinal 266 
immune status can therefore be rapidly relayed to the CNS, and may play a critical role in neural 267 
reflexes and behavioural responses [41,42]. 268 
Conclusions and possible implications for therapy and policy 269 
The prescribed dose of ranitidine was the maximum recommended daily dose for the drug. Patients 270 
referred for gastroscopy are advised to stop taking medications that interfere with gastric acid 271 
production; this includes proton pump inhibitors and H2 receptor antagonists. Advice varies as to 272 
when medication should be interrupted and usually recommends cessation one or two weeks before 273 
the procedure. There is no recommendation to taper the dose of H2 antagonists leading to stoppage. 274 
Gradual reduction in dose, leading to stoppage, may or may not have been sufficient to avoid or 275 
reduce symptoms associated with excess histamine, or enhanced histamine sensitivity, in this 276 
patient. As described above, rebound hyperacidity following abrupt cessation of H2 antagonists is 277 
well-documented. Outstanding questions relate to whether the reaction reported here occurred as a 278 
consequence of the prior high dose and duration of ranitidine treatment; the abruptness of 279 
cessation; the patient’s disorder of mast cell activation (and hEDS); or a combination of some or all 280 
of these factors. It is proposed that further investigation of widespread histaminergic symptoms in 281 
relation to cessation of H2 antagonists may be of benefit, and in particular amongst this population 282 
who may be at increased risk.  283 
Nomenclature of Targets and Ligands 284 
 Key protein targets and ligands in this article are hyperlinked to corresponding entries in 285 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 286 
PHARMACOLOGY [43], and are permanently archived in the Concise Guide to PHARMACOLOGY 287 
2017/18 [44]. 288 
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